We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Filters

Equity Crowdfunding Pitches

Showing results
Skin In Motion (SIM) is a first-of-its-kind exercise-friendly beauty range that seeks to promote the positive effects of exercise through healthy and confidence-boosting skincare and makeup products specifically designed to be worn pre, during, and post-exercise. SIM claims that its products are available Direct To Consumer (DTC) via its website and are listed on LookFantastic, Amazon and Oliver Bonas. SIM was awarded the 'Best New Business 2020' award by the Women's Business Club. The brand has reached 3 million potential customers and has an Instagram following of 3,000 to date. The company has also featured in Sunday Times Style Magazine, Hello!, RED Magazine, and Women's Health, to name a few. It will use the investment to grow its team, increase marketing and brand awareness, and accelerate new product developments.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £166,111
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £134,892
South Shields Football Club aims to break into the Football League (FL). Between 1919 and 1930, South Shields had a club which at times thrived in the second tier of the FL. In 2020, the club successfully steered its way through the challenges of the COVID-19 lockdown by taking advantage of the grants available from the government and executing other fundraising activities. The club feels the experience has made them stronger and more determined than ever to achieve their long term goals. It will use 62% of the investment to replace its stadium's current dilapidated pitchside barrier with new ones and 38% as working capital that it will use through the next 12 months as it moves towards a sustainable model.

Pitch Rated

62%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £379,025
Richard Brendon is a prominent British design brand that values master craftspeople by creating a platform for contemporary and timeless tableware collections that challenge the expected. It has received extensive media coverage since 2013 including the FT and NY Times. The company has sold to more than 120 B2B customers in 15 countries. It has seen a growth of 75% since 2015 amounting to £2.5m sales to date and more than 3,000 orders delivered. Richard now plans to take his brand global. It has enjoyed a CAGR of 75% from 2015 to 2019, with revenue of £1.12m in 2019. The company plans on opening up new markets, creating four additional collections over the coming years to develop existing channels and territories.

Pitch Rated

74%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £250,350
Lime Global is a UK-based company dedicated to becoming the most customer-focused provider of health cover. Lime argues that conventional health insurance is too expensive and overly complicated. It intends to make health insurance affordable allowing customers to buy the top-ups they want without consulting advisers or filling long questionnaires. Lime Global claims to provide customers with a cancer cover providing a lump sum and support following diagnosis, access to 'Rapid Diagnostics' to avail private diagnostic tests, and an online platform where customers and employers can book and pay for clinical services. Lime Global aspires to become a contender in the UK private healthcare market set to grow more than £8 billion. The company points out that it has secured 5 star Trustpilot reviews over the last year with zero complaints to date. They intend to use the investment to support their expansion into Small and Medium Enterprises (SMEs), mental health modules and e-pharmacies, scale customer acquisition, and support the next stage of its growth in late 2021 and early 2022.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £474,838
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.

Pitch Rated

56%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,835,892
Nexus is a digital platform that empowers users to take control of their health and wellbeing. It states that long-term health conditions like diabetes and cancer will account for over 50% of global health spending by the end of 2021 with depression becoming the leading cause of disability. Nexus aims to address this situation via its app. It argues that its app will offer users health coaching, telemental health, products, and services to transform their lifestyle. Nexus claims that the app can track progress via self-entered user data and is being designed to connect with apps and wearables to inspire life-long behavioural change. Nexus has prepared a pilot for an NHS Trust endorsed by Boston Scientific with a collaboration agreement to roll out the app to 30,000 NHS users. Nexus was one of 100 startups chosen to pitch at the World Business Angels Forum 2020. The Company says that it will use the investment to support Phase 2 of its tech build, grow further in the UK, and start its expansion in the UAE.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £280,360
Alphagreen is Europe's largest online marketplace for Cannabidiol (CBD) healthcare products listing over 150 brands and more than 2,500 products on its portal. It claims that it is backed by high-profile cannabis investors like Enexis, West Creek Investments, and others. It aspires to become the leader in the CBD market that is expected to be worth over £900 million in 2025 in the UK alone. Alphagreen aspires to build a trusted ecosystem for customers with Sleep, Pain and Anxiety problems, enable them to access alternative healthcare, and distribute medical cannabis from Q3 of 2021. The company has featured in Forbes, Business Insider, Prohibition Partners, The Financial Times, and The Grocer. It will use 31% of the investment for sales and marketing, 25% for team expansion, 16% for general corporate affairs, 15% for international expansion, and 13% for technology up-gradation.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £2,039,375
QFinds is a purpose-built hiring tool that enables employers to easily and efficiently pre-screen candidates, conduct interviews and generate employment contracts. The company asserts that it is a UK government vetted 'Kickstart Scheme' representative and can get small businesses grants to hire interns having already processed over 100 job applications. QFinds claims that its app has been downloaded 2 million+ times garnering 24,000 reviews averaging 4.8/5 stars. QFinds also points out that bad hirings cost the UK up to £6.7 billion in turnover, productivity, and training. It seeks to change this and disrupt the £39 billion recruitment market. The company has partnered with notable entities like University College London, Kings College London and Brunel University London, intending to use them as strategic partners to increase job seekers signing up to and using its app. QFinds will use the investment to grow its business across different verticals.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £222,866
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £388,038
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph